Literature DB >> 18047848

Lipids, lipoproteins, and peroxisome proliferator activated receptor-delta.

Dennis L Sprecher1.   

Abstract

Peroxisome proliferator activated receptors (PPARs) are nuclear receptors activated by small, lipophilic compounds. Typically resident on nuclear DNA, full activation requires heterodimer formation with retinoid X receptor and ligand binding, leading to modulation in the expression of hundreds of genes. Of the 3 described forms, (PPAR-alpha, PPAR-gamma, and PPAR-delta), PPAR-delta has been the least investigated. Preclinical in vitro data show that activation of PPAR-delta, like PPAR-alpha, results in enhancement of fatty acid oxidation, leading to increased energy production in the form of adenosine triphosphate and of energy uncoupling. Microarray data in preclinical models suggest substantial PPAR-delta expression in skeletal muscle. Exercise, which induces upregulation of PPAR-delta in muscle tissue, leads to an increased requirement for an external or serum derived triacylglycerol energy source. This suggests that upregulation of skeletal muscle PPAR-delta would influence lipoprotein composition, this being the major source of combustible substrate. In the first human study using a PPAR-delta agonist, experimental data obtained with GW 501516 (a highly specific PPAR-delta agonist) suggested that upregulated enzymes critical to fatty acid oxidation in human cells enhanced fatty acid and beta-oxidation in skeletal muscle.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18047848     DOI: 10.1016/j.amjcard.2007.08.009

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  11 in total

1.  Regulating PPARδ signaling as a potential therapeutic strategy for skeletal muscle disorders in heart failure.

Authors:  Ronald B Myers; Jun Yoshioka
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-03-13       Impact factor: 4.733

2.  Rationally designed PPARδ-specific agonists and their therapeutic potential for metabolic syndrome.

Authors:  Rebecca L Cox
Journal:  Proc Natl Acad Sci U S A       Date:  2017-03-20       Impact factor: 11.205

3.  Research resource: nuclear receptor atlas of human retinal pigment epithelial cells: potential relevance to age-related macular degeneration.

Authors:  Mary A Dwyer; Dmitri Kazmin; Peng Hu; Donald P McDonnell; Goldis Malek
Journal:  Mol Endocrinol       Date:  2011-01-14

Review 4.  Peroxisome proliferator-activated receptors, metabolic syndrome and cardiovascular disease.

Authors:  Salman Azhar
Journal:  Future Cardiol       Date:  2010-09

5.  Long chain acyl-CoA synthetase-3 is a molecular target for peroxisome proliferator-activated receptor delta in HepG2 hepatoma cells.

Authors:  Aiqin Cao; Hai Li; Yue Zhou; Minhao Wu; Jingwen Liu
Journal:  J Biol Chem       Date:  2010-03-22       Impact factor: 5.157

6.  Effect of dietary monosodium glutamate on trans fat-induced nonalcoholic fatty liver disease.

Authors:  Kate S Collison; Zakia Maqbool; Soad M Saleh; Angela Inglis; Nadine J Makhoul; Razan Bakheet; Mohammed Al-Johi; Rana Al-Rabiah; Marya Z Zaidi; Futwan A Al-Mohanna
Journal:  J Lipid Res       Date:  2008-11-11       Impact factor: 5.922

7.  May diet and dietary supplements improve the wellness of multiple sclerosis patients? A molecular approach.

Authors:  Paolo Riccio; Rocco Rossano; Grazia Maria Liuzzi
Journal:  Autoimmune Dis       Date:  2011-02-24

8.  Novel Benzylidene Thiazolidinedione Derivatives as Partial PPARγ Agonists and their Antidiabetic Effects on Type 2 Diabetes.

Authors:  Sabina Yasmin; Fabio Capone; Antonio Laghezza; Fabrizio Dal Piaz; Fulvio Loiodice; Viswanathan Vijayan; Velmurugan Devadasan; Susanta K Mondal; Özlem Atlı; Merve Baysal; Ashok K Pattnaik; Venkatesan Jayaprakash; Antonio Lavecchia
Journal:  Sci Rep       Date:  2017-10-31       Impact factor: 4.379

9.  MBX-102/JNJ39659100, a novel non-TZD selective partial PPAR-γ agonist lowers triglyceride independently of PPAR-α activation.

Authors:  Apurva Chandalia; Holly J Clarke; L Edward Clemens; Bindu Pandey; Vic Vicena; Paul Lee; Brian E Lavan; Francine M Gregoire
Journal:  PPAR Res       Date:  2009-04-23       Impact factor: 4.964

10.  PPAR Ligands as Potential Modifiers of Breast Carcinoma Outcomes.

Authors:  Ancha Baranova
Journal:  PPAR Res       Date:  2008       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.